Thyroid hormone receptors, coregulators, and disease

NR Coregulators and Human Diseases

Volumn , Issue , 2008, Pages 256-293

  Privalsky, Martin L ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84969590464     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789812819178_0006     Document Type: Chapter

References (98)

1. Larsen PR, Davies TF, Schlumberger MJ, et al., Thyroid physiology and diagnostic evaluation of patients with thyroid disorders, in Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds.), Williams Textbook of Endocrinology, Saunders, Philadelphia, pp. 331-373, 2003.
2. Bassett JH, Harvey CB, Williams GR, Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions, Mol Cell Endocrinol 213:1-11, 2003.
3. O’Shea PJ, Williams GR, Insight into the physiological actions of thyroid hormone receptors from genetically modified mice, J Endocrinol 175:553-570, 2002.
4. Wondisford FE, Thyroid hormone action: Insight from transgenic mouse models, J Investig Med 51:215-220, 2003.
5. Rastinejad F, Retinoid X receptor and its partners in the nuclear receptor family, Curr Opin Struct Biol 11:33-38, 2001
6. Forman BM, Casanova J, Raaka BM, et al., Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers, Mol Endocrinol 6:429-442, 1992.
7. Lazar MA, Berrodin TJ, Harding HP Differential DNA binding by monomeric, homodimeric, and potentially heteromeric forms of the thyroid hormone receptor, Mol Cell Biol 11:5005-5015, 1991.
8. Lee S, Privalsky ML, Heterodimers of retinoic acid receptors and thyroid hormone receptors display unique combinatorial regulatory properties, Mol Endocrinol 19:863-878, 2005.
9. Mengeling BJ, Pan F, Privalsky ML, Novel mode of deoxyribonucleic acid recognition by thyroid hormone receptors: Thyroid hormone receptor S-isoforms can bind as trimers to natural response elements comprised of reiterated half-sites, Mol Endocrinol 19:35-51, 2005.
10. Tini M, Tsui LC, Giguere V, Heterodimeric interaction of the retinoic acid and thyroid hormone receptors in transcriptional regulation on the yF-crystallin everted retinoic acid response element, Mol Endocrinol 8:1494-1506, 1994.
11. Wagner RL, Apriletti JW, McGrath ME, et al., A structural role for hormone in the thyroid hormone receptor, Nature (London) 378:690-697, 1995.
12. Glass CK, Rosenfeld MG, The coregulator exchange in transcriptional functions of nuclear receptors, Genes Dev 14:121-141, 2000.
13. Privalsky ML, The role of corepressors in transcriptional regulation by nuclear hormone receptors, Annu Rev Physiol 66:315-360, 2004.
14. Feng X, Jiang Y, Meltzer P, et al., Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray, Mol Endocrinol 14:947-955, 2000.
15. White JH, Fernandes I, Mader S, et al., Corepressor recruitment by agonist-bound nuclear receptors, Vitam Horm 68:123-143, 2004.
16. Ortiga-Carvalho TM, Shibusawa N, Nikrodhanond A, et al., Negative regulation by thyroid hormone receptor requires an intact coactivator- binding surface, J Clin Invest 115:2517-2523, 2005.
17. Tagami T, Park Y, Jameson JL, Mechanisms that mediate negative regulation of the thyroid-stimulating hormone a gene by the thyroid hormone receptor, J Biol Chem 274:22345-22353, 1999.
18. Xu W, Chen H, Du K, et al., A transcriptional switch mediated by cofactor methylation, Science 294:2507-2511, 2001.
19. Jepsen K, Rosenfeld MG, Biological roles and mechanistic actions of co-repressor complexes, J Cell Sci 115:689-698, 2002.
20. Jones PL, Shi YB, N-CoR-HDAC corepressor complexes: Roles in transcriptional regulation by nuclear hormone receptors, Curr Top Microbiol Immunol 274:237-268, 2003.
21. Ordentlich P Downes M, Evans RM, Corepressors and nuclear hormone receptor function, Curr Top Microbiol Immunol 254:101-116, 2001.
22. Goodson M, Jonas BA, Privalsky MA, Corepressors: Custom tailoring and alterations while you wait, Nucl Recept Signal 3:e003, 2005.
23. Dilworth FJ, Chambon P Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription, Oncogene 20:3047-3054, 2001.
24. Lee JW, Lee YC, Na SY, et al., Transcriptional coregulators of the nuclear receptor superfamily: Coactivators and corepressors, Cell Mol Life Sci 58:289-297, 2001.
25. Tsai CC, Fondell JD, Nuclear receptor recruitment of histone-modifying enzymes to target gene promoters, Vitam Horm 68:93-122, 2004.
26. McKenna NJ, Xu J, Nawaz Z, et al., Nuclear receptor coactivators: Multiple enzymes, multiple complexes, multiple functions, J Steroid Biochem Mol Biol 69:3-12, 1999.
27. Weiss RE, Ramos HE, Thyroid hormone receptor subtypes and their interaction with steroid receptor coactivators, Vitam Horm 68:185-207, 2004.
28. Alenghat T, Yu J, Lazar MA, The N-CoR complex enables chromatin remodeler SNF2H to enhance repression by thyroid hormone receptor, EMBO J 25:3966-3974, 2006.
29. Kraus WL, Wong J, Nuclear receptor-dependent transcription with chromatin. Is it all about enzymes? Eur J Biochem 269:2275-2283, 2002.
30. Perissi V, Aggarwal A, Glass CK, et al., A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors, Cell 116:511-526, 2004.
31. Chatterjee VK, Resistance to thyroid hormone, and peroxisome-proliferator- activated receptor gamma resistance, Biochem Soc Trans 29:227-231, 2001.
32. Refetoff S, Resistance to thyroid hormone with and without receptor gene mutations, Ann Endocrinol (Paris) 64:23-25, 2003.
33. Yen PM, Molecular basis of resistance to thyroid hormone, Trends Endocrinol Metab 14:327-333, 2003.
34. Safer JD, Cohen RN, Hollenberg AN, et al., Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone, J Biol Chem 273:30175-30182, 1998.
35. Tagami T, Jameson JL, Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone, Endocrinology 139:640-650, 1998.
36. Yoh SM, Chatterjee VK, Privalsky ML, Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors, Mol Endocrinol 11:470-480, 1997.
37. Lin BC, Hong SH, Krig S, et al., A conformational switch in nuclear hormone receptors is involved in coupling hormone binding to corepressor release, Mol Cell Biol 17:6131-6138, 1997.
38. Tagami T, Gu WX, Peairs PT, et al., A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators, Mol Endocrinol 12:1888-1902, 1998.
39. Collingwood TN, Adams M, Tone Y, et al., Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone 8-receptors in thyroid hormone resistance syndrome, Mol Endocrinol 8:1262-1277, 1994.
40. Forman BM, Yang CR, Au M, et al., A domain containing leucine-zipperlike motifs mediate novel in vivo interactions between the thyroid hormone and retinoic acid receptors, Mol Endocrinol 3:1610-1626, 1989.
41. Matsushita A, Misawa H, Andoh S, et al., Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT, J Endocrinol 167:493-503,2000.
42. Nagaya T, Fujieda M, Seo H, Requirement of corepressor binding of thyroid hormone receptor mutants for dominant negative inhibition, Biochem Biophys Res Commun 247:620-623, 1998.
43. Yoh SM, Privalsky ML, Resistance to thyroid hormone (RTH) syndrome reveals novel determinants regulating interaction of T3 receptor with corepressor, Mol Cell Endocrinol 159:109-124, 2000.
44. Wu SY, Cohen RN, Simsek E, et al., A novel thyroid hormone receptor-8 mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone, J Clin Endocrinol Metab 91:1887-1895, 2006.
45. Flamant F, Gauthier K, Samarut J, Thyroid hormones signaling is getting more complex: STORMs are coming, Mol Endocrinol 21:321-333, 2007.
46. Liu Y, Takeshita A, Misiti S, et al., Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors, Endocrinology 139:4197-4204, 1998.
47. Cheng SY, Isoform-dependent actions of thyroid hormone nuclear receptors: Lessons from knockin mutant mice, Steroids 70:450-454, 2005.
48. Zhang XY, Kaneshige M, Kamiya Y, et al., Differential expression of thyroid hormone receptor isoforms dictates the dominant negative activity of mutant 8 receptor, Mol Endocrinol 16:2077-2092, 2002.
49. O’Shea PJ, Bassett JH, Cheng SY, et al., Characterization of skeletal phenotypes of TRa1 and TRS mutant mice: Implications for tissue thyroid status and T3 target gene expression, Nucl Recept Signal 4:e011, 2006.
50. Ying H, Araki O, Furuya F, et al., Impaired adipogenesis caused by a mutated thyroid hormone a1 receptor, Mol Cell Biol 27:2359-2371, 2007.
51. Safer JD, Langlois MF, Cohen R, et al., Isoform variable action among thyroid hormone receptor mutants provides insight into pituitary resistance to thyroid hormone, Mol Endocrinol 11:16-26, 1997.
52. Oberste-Berghaus C, Zanger K, Hashimoto K, et al., Thyroid hormone- independent interaction between the thyroid hormone receptor p2 amino terminus and coactivators, J Biol Chem 275:1787-1792, 2000.
53. Tian H, Mahajan MA, Wong CT, et al., The N-Terminal A/B domain of the thyroid hormone receptor-82 isoform influences ligand-dependent recruitment of coactivators to the ligand-binding domain, Mol Endocrinol 20:2036-2051, 2006.
54. Yang Z, Privalsky ML, Isoform-specific transcriptional regulation by thyroid hormone receptors: Hormone-independent activation operates through a steroid receptor-mode of coactivator interaction, Mol Endocrinol 15:1170-1185, 2001.
55. Wan W, Farboud B, Privalsky ML, Pituitary resistance to thyroid hormone syndrome is associated with T3 receptor mutants that selectively impair S2 isoform function, Mol Endocrinol 19:1529-1542, 2005.
56. Ono S, Schwartz ID, Mueller OT, et al., Homozygosity for a dominant negative thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone, J Clin Endocrinol Metab 73:990-994, 1991.
57. Beug H, Bauer A, Dolznig H, et al., Avian erythropoiesis and ery- throleukemia: Towards understanding the role of the biomolecules involved, Biochim Biophys Acta 1288:M35-M47, 1996.
58. Privalsky ML, V-erb A, nuclear hormone receptors, and oncogenesis, Biochim Biophys Acta 1114:51-62, 1992.
59. Zenke M, Munoz A, Sap J, et al., V-erb A oncogene activation entails the loss of hormone-dependent regulator activity of c-erb A, Cell 61:1035-1049, 1990.
60. Barlow C, Meister B, Lardelli M, et al., Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erb A, EMBO J 13:4241-4250, 1994, 1991.
61. Gandrillon O, Jurdic P Pain B, et al., Expression of the v-erb A product, an altered nuclear hormone receptor, is sufficient to transform erythrocytic cells in vitro, Cell 58:115-121, 1989.
62. Mosesson Y, Yarden Y, Oncogenic growth factor receptors: Implications for signal transduction therapy, Semin Cancer Biol 14:262-270, 2004.
63. O’Shea PJ, Bassett JH, Sriskantharajah S, et al., Contrasting skeletal phenotypes in mice with an identical mutation targeted to thyroid hormone receptor a1 or S, Mol Endocrinol 19:3045-3059, 2005.
64. Lee S, Privalsky ML, Multiple mutations contribute to repression by the v-Erb A oncoprotein, Oncogene 24:6737-6752, 2005.
65. Zubkova I, Subauste JS, V-erb A homodimers mediate the potent dominant negative activity of V-erb A on everted repeats, Mol Biol Rep 31:131-137, 2004.
66. Judelson C, Privalsky ML, DNA recognition by normal and oncogenic thyroid hormone receptors. Unexpected diversity in half-site specificity controlled by non-zinc-finger determinants, J Biol Chem 271:10800-10805, 1996.
67. Bonde BG, Sharif M, Privalsky ML, Ontogeny of the V-erb A oncoprotein from the thyroid hormone receptor: An alteration in the DNA binding domain plays a role crucial for V-erb A function, J Virol 65:2037-2046, 1991.
68. Rietveld LE, Caldenhoven E, Stunnenberg HG, Avian erythroleukemia: A model for corepressor function in cancer, Oncogene 20:3100-3109, 2001.
69. Sharif M, Privalsky ML, V-erb A oncogene function in neoplasia correlates with its ability to repress retinoic acid receptor action, Cell 66:885-893,1991.
70. Schroeder C, Gibson L, Zenke M, et al., Modulation of normal erythroid differentiation by the endogenous thyroid hormone and retinoic acid receptors: A possible target for V-erb A oncogene action, Oncogene 7:217-227, 1992.
71. Desbois C, Pain B, Guilhot C, et al., V-erb A oncogene abrogates growth inhibition of chicken embryo fibroblasts induced by retinoic acid, Oncogene 6:2129-2135, 1991.
72. Sharif M, Privalsky ML, V-erb A and c-erb A proteins enhance transcriptional activation by c-Jun, Oncogene 7:953-960, 1992.
73. Lin KH, Zhu XG, Hsu HC, et al., Dominant negative activity of mutant thyroid hormone a1 receptors from patients with hepatocellular carcinoma, Endocrinology 138:5308-5315, 1997.
74. Lin KH, Shieh HY, Chen SL, et al., Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells, Mol Carcinog 26:53-61, 1999.
75. Chan IH, Privalsky ML, Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs, Oncogene 25:3576-3588, 2006.
76. Lin KH, Wu YH, Chen SL, Impaired interaction of mutant thyroid hormone receptors associated with human hepatocellular carcinoma with transcriptional coregulators, Endocrinology 142:653-662, 2001.
77. Cheng SY, Thyroid hormone receptor mutations and disease: Beyond thyroid hormone resistance, Trends Endocrinol Metab 16:176-182, 2005.
78. Gonzalez-Sancho JM, Garcia V, Bonilla F, et al., Thyroid hormone recep- tors/THR genes in human cancer, Cancer Lett 192:121-132, 2003.
79. Kamiya Y, Puzianowska-Kuznicka M, McPhie P et al., Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma, Carcinogenesis 23:25-33, 2002.
80. Cheng SY, Abnormalities of nuclear receptors in thyroid cancer, Cancer Treat Res 122:165-178, 2004.
81. Puzianowska-Kuznicka M, Krystyniak A, Madej A, et al., Functionally impaired TR mutants are present in thyroid papillary cancer, J Clin Endocrinol Metab 87:1120-1128, 2002.
82. Suzuki H, Willingham MC, Cheng SY, Mice with a mutation in the thyroid hormone receptor 8 gene spontaneously develop thyroid carcinoma: A mouse model of thyroid carcinogenesis, Thyroid 12:963-969, 2002.
83. Insinga A, Pelicci PG, Inucci S, Leukemia-associated fusion proteins. Multiple mechanisms of action to drive cell transformation, Cell Cycle 4:67-69, 2005.
84. Redner RL, Variations on a theme: The alternate translocations in APL, Leukemia 16:1927-1932, 2002.
85. Lin RJ, Evans RM, Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers, Mol Cell 5:821-830, 2000.
86. Minucci S, Maccarana M, Cioce M, et al., Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation, Mol Cell 5:811-820, 2000.
87. He LZ, Guidez F, Tribioli C, et al., Distinct interactions of PML-RARa and PLZF-RARa with co-repressors determine differential responses to RA in APL, Nat Genet 18:126-135, 1998.
88. Hong SH, David G, Wong CW, et al., SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor a (RARa) and PLZF-RARa oncoproteins associated with acute promyelocytic leukemia, Proc Natl Acad Sci USA 94:9028-9033, 1997.
89. Grignani F, De Matteis S, Nervi C, et al., Fusion proteins of the retinoic acid receptor-a recruit histone deacetylase in promyelocytic leukaemia, Nature (London) 391:815-818, 1998.
90. Guidez F, Ivins S, Zhu J, et al., Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARa underlie molecular pathogenesis and treatment of acute promyelocytic leukemia, Blood 91:2634-2642, 1998.
91. Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia, Nature (London) 391:811-814, 1998.
92. Hong SH, Yang Z, Privalsky ML, Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with its transcription factor partners, including the PML-RARa oncoprotein found in human acute promyelo- cytic leukemia, Mol Cell Biol 21:7172-7182, 2001
93. Chen Z, Zhao WL, Shen ZX, et al., Arsenic trioxide and acute promyelo- cytic leukemia: Clinical and biological, Curr Top Microbiol Immunol 313:129-144, 2007.
94. Hayakawa F, Privalsky ML, Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis, Cancer Cell 5:389-401, 2004.
95. Hauksdottir H, Privalsky ML, DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia, Cell Growth Differ 12:85-98, 2001.
96. Zhou J, Peres L, Honore N, et al., Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARa- induced immortalization, Proc Natl Acad Sci USA 103:9238-9243, 2006.
97. Semple RK, Chatterjee VK, O’Rahilly S, PPARy and human metabolic disease, J Clin Invest 116:581-589, 2006.
98. Agostini M, Schoenmakers E, Mitchell C, et al., Non-DNA binding dominant-negative, human PPARymutations cause lipodystrophic insulin resistance, Cell Metab 4:303-311, 2006.